GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare announced a new artificial intelligence application it said will save time for doctors who diagnose and treat cancer. The tool, called CareIntellect for Oncology, can quickly summarize patients' histories, monitor disease progression and identify relevant clinical trials, the company said.

GE HealthCare announces time-saving AI tool for doctors who treat cancer

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced CareIntellect for Oncology, a new cloud-first application that brings together multi-modal patient data from disparate systems into a single view, using generative AI to summarize clinical notes and reports. The application also surfaces relevant data allowing care teams to quickly understand disease progression and flag potential deviations from the treatment plan to help the clinician determine potential next steps and inf.

GE HealthCare announces CareIntellect for Oncology, harnessing AI to give clinicians an easy way to see the patient journey in a single view

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a new AI Innovation Lab, an initiative designed to accelerate early-concept AI innovations within the company. These projects are one part of GE HealthCare's broader AI and digital strategy, which is focused on integrating AI into medical devices, building AI applications that enhance decision-making across the care journey and disease states, and using AI to support better outcomes and operational efficiencies system-wide.

GE HealthCare Announces AI Innovation Lab Showcasing Five New Research Projects

MILWAUKEE--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), the GE HealthCare Foundation, and the Charles Antetokounmpo Family Foundation (CAFF), teamed up to launch a new philanthropic endeavor, Powering Milwaukee Forward, aimed at improving access to basic needs within Milwaukee's underserved communities. The initiative will grant 10 area nonprofits a total of $1 million. “The City of Milwaukee has done so much for me and my family – but I know there are so many in this community who struggle t.

GE HealthCare, the GE HealthCare Foundation, and the Charles Antetokounmpo Family Foundation commit $1M to improve Milwaukee health outcomes

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a new tile for its Command Center Software: Hospital Pulse. Hospital Pulse Tile pulls in real-time information from across departments to quickly surface the most vital information about a healthcare system's operations in a customizable dashboard designed to give operation leaders the quick “pulse check” they need to make adjustments throughout the day. For example, the tile can be configured to show how the number of emerg.

GE HealthCare announces major academic medical center as first customer to adopt new Hospital Pulse Tile for Command Center

CHICAGO--(BUSINESS WIRE)--With the aim of increasing access to precision care, GE HealthCare is proud to collaborate with University Medicine Essen (UME) in the establishment of a new Theranostics Center of Excellence. The Center will be outfitted with the latest technologies and solutions to support the clinical practice and advanced research of more personalized approaches to cancer care in Germany and around the world. Cancerous diseases continue to threaten the lives of patients, with over.

A New Theranostics Center of Excellence in Europe: GE HealthCare and University Medicine Essen Collaborate to Advance Theranostics and Personalized Medicine

GEHC launches Versana Premier, an AI-powered ultrasound system with advanced features designed for efficient, high-quality diagnostics across multiple specialties.

GE HealthCare's Shares Rise After the Launch of Versana Premier

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of the new Versana Premier™, the latest release within the Versana ultrasound family of reliable, affordable, easy-to-use, and versatile ultrasound systems. Versana Premier offers automation and AI-enabled productivity tools to improve workflow and clinical features designed to enhance clinical efficiency and accuracy, all while delivering an effortless user experience and helping clinicians best meet their patien.

GE HealthCare introduces easy-to-use, easy-to-learn, easy-to-diagnose Versana Premier multi-purpose ultrasound system

GEHC acquires clinical AI business to aid its ultrasound portfolio with AI-driven image analysis tools.

GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business

GE Healthcare's MIM Software announces the FDA clearance of Monte Carlo Dosimetry for Theranostics, enhancing precision in personalized treatment plans.

GEHC's MIM Software to Aid Radiation Therapy With Its Latest FDA Nod

CHICAGO--(BUSINESS WIRE)--GE HealthCare integrates third party artificial intelligence (AI)-enabled application orchestration feature into True PACS and Centricity PACS. 1 In collaboration with Blackford, the new AI-enabled offerings help radiologists with their workload which could help lead to quicker diagnosis and treatment for patients. The collaboration is intended to offer health care providers an AI-enabled platform with a catalogue of third-party AI applications that span across various.

GE HealthCare Accelerates Artificial Intelligence Adoption With New Offering to Advance Enterprise Imaging

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also wi.

GE HealthCare to announce third quarter 2024 results on October 30, 2024

CHICAGO--(BUSINESS WIRE)--GE HealthCare announces the commencement, and its leading industrial role, in Thera4Care, an initiative aimed at revolutionizing the use of theranostics to broaden patient access in Europe. The €25.3 million project gathers 29 partners from top European academic and clinical sites, small and medium-sized enterprises, and patient advocacy groups. Cancer is the leading cause of death worldwide, accounting for nearly ten million deaths in 2022. By 2050, the global burden.

GE HealthCare takes key role in new consortium to revolutionize cancer care, advancing precision medicine for patients in Europe

CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent.

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

GEHC's Flyrcado, a first-of-its-kind PET tracer for coronary artery disease, receives FDA approval, expanding diagnostic access and improving patient outcomes.

GE HealthCare Stock Likely to Rise After FDA Approval of Flyrcado

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery disease, the company said on Friday.

US FDA approves GE HealthCare's diagnostic drug for heart disease

ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease.

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease

Shares of GE HealthCare Technologies Inc (NASDAQ:GEHC), a spinoff of General Electric (GE) , are down 1.9% before the opening bell after a bear note from UBS.

Analyst: Healthcare Stock Faces 2 Key Pressure Points

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its latest innovations in radiation oncology that will be showcased at the American Society for Radiation Oncology (ASTRO) 2024 conference in Washington, DC. These novel solutions aim to improve the entirety of the radiation therapy workflow for clinicians and cancer patients. It is estimated that 470,000 patients receive radiotherapy each year in the U.S. and more than half of patients with cancer will receive radiotherapy.

GE HealthCare Showcases the Latest AI-enhanced Radiation Therapy Solutions at ASTRO 2024

GEHC introduces Venue Sprint, a portable AI-enabled ultrasound device offering wireless probes, real-time insights and advanced clinical tools for improved care.

GE HealthCare Shares Rise After AI-Powered Venue Sprint's Launch

GE Healthcare's MIM Software announces the receipt of FDA clearance for its Centiloid scaling tool to perform PET-based amyloid imaging.

GEHC Stock Rises as FDA Clears MIM Software's Centiloid Tool

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of enhanced Venue ultrasound systems and a new solution setting the pace of point-of-care ultrasound (POCUS): Venue Sprint. The Venue Sprint is a new ultrasound device designed for maximum portability that combines the powerful, familiar Venue software and AI-enabled tools, uncompromised image quality, and wireless probe capability with Vscan Air handheld ultrasound systems. Other Venue family ultrasound systems w.

GE HealthCare introduces elevated Venue point of care ultrasound solutions and new tablet-based Venue Sprint

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data anal.

GE HealthCare announces cash dividend for third quarter of 2024

GE HealthCare Technologies has shown promising performance, with a 12% stock increase since June, outperforming the S&P 500's 2.9% rise. Despite some revenue declines in key segments, the PDx segment's 12.5% growth and overall profitability improvements are encouraging. Management's revised guidance suggests a positive outlook, with expected EPS growth and improved EBIT margins, indicating strong future potential.

GE HealthCare: The Image Of More Upside Is Very Real

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

News for GE HealthCare Technologies Inc Stock (GEHC)